Clinical trials: Granulomatosis With Polyangitis
Granulomatosis With Polyangiitis, Wegener Granulomatosis
The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach
This is a randomized controlled trial in patients with a diagnosis of granulomatosis with polyangiitis (GPA; Wegener's)that are in remission to evaluate the effects of using low-dose glucocorticoids ( 5 mg/day of prednisone) as…
- Conditions
- Granulomatosis With Polyangiitis, Wegener Granulomatosis, Vasculitis
- Trial name
- TAPIR (NCT01933724)
- Testing
- 5 mg prednisone, 0 mg prednisone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of South Florida
ANCA Associated Vasculitis, Microscopic Polyangiitis
Hydroxychloroquine in ANCA Vasculitis Evaluation
The purpose of this study is to find out whether hydroxychloroquine, in addition to background treatments, reduces disease activity in patients with Anti-Neutrophilic Cytoplasmic Autoantibodies (ANCA) Vasculitis, a group of…
- Conditions
- ANCA Associated Vasculitis, Microscopic Polyangiitis, Churg-Strauss Syndrome, Wegener Granulomatosis
- Trial name
- HAVEN (NCT04316494)
- Testing
- Hydroxychloroquine
- Where
- 18 sites in United Kingdom
- Volunteers
- 43 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Inflammation, Vasculitis
Analysis of Bronchial Tissue and Fluid in Patients With Wegener's Granulomatosis
This study will collect fluid and tissue samples from the bronchi (air passages to the lungs) of patients with Wegener's granulomatosis for laboratory examination.
- Conditions
- Inflammation, Vasculitis, Wegener's Granulomatosis
- Trial name
- NCT00001541
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Giant Cell Arteritis, Takayasu's Arteritis
Reproductive Health in Men and Women With Vasculitis
The purpose of this study is to learn about reproductive health, including fertility and pregnancies, in people with vasculitis.
- Conditions
- Giant Cell Arteritis, Takayasu's Arteritis, Polyarteritis Nodosa, Wegener's Granulomatosis
- Trial name
- NCT02176070
- Where
- United States
- Volunteers
- 467 people
- Sponsor
- University of South Florida
MPA, PAN or EGPA With FFS=0
Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome)
To determine whether a combination of corticosteroids and azathioprine can achieve a higher remission rate and a lower subsequent relapse rate in patients with newly-diagnosed microscopic polyangiitis, polyarteritis nodosa or…
- Conditions
- MPA, PAN or EGPA With FFS=0, At Diagnosis or Within the First 15 Days Following Initiation of Corticosteroids
- Trial name
- CHUSPAN2 (NCT00647166)
- Testing
- corticosteroid and azathioprine
- Where
- France
- Volunteers
- 114 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Rituximab in Eosinophilic Granulomatosis With Polyangiitis
Phase III, comparative, multicenter, randomized, controlled, double-blind and superiority research, comparing rituximab-based regimen with conventional therapeutic strategy for the induction of remission in patients with…
- Trial name
- REOVAS (NCT02807103)
- Testing
- Rituximab, Cyclophosphamide
- Where
- France
- Volunteers
- 107 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Eosinophilic Granulomatous Vasculitis
Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.
This is a randomized, double blind, active-controlled, parallel group, multicenter 52-week Phase 3 study to compare the efficacy and safety of benralizumab 30 mg versus mepolizumab 300 mg administered by subcutaneous (SC)…
- Trial name
- MANDARA (NCT04157348)
- Testing
- Benralizumab, Mepolizumab
- Where
- 50 sites in United States, Belgium and 7 more
- Volunteers
- 140 people
- Sponsor
- AstraZeneca
Eosinophilic Granulomatosis With Polyangiitis
Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge)
The purpose of this study is to compare mepolizumab-based regimen to conventional therapeutic strategy for remission induction in patients with Eosinophilic Granulomatosis with Polyangiitis.
- Trial name
- E-merge (NCT05030155)
- Testing
- Mepolizumab, cyclophosphamide/azathioprine
- Where
- France
- Volunteers
- 102 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Systemic Wegener's Granulomatosis
WEGENT - Comparison of Methotrexate or Azathioprine as Maintenance Therapy for ANCA-Associated Vasculitides
Remission of ANCA-associated vasculitis can be obtained in approximately 80% of the patients with a combination of corticosteroids and cyclophosphamide. However, relapses are frequent.
- Trial name
- NCT00349674
- Testing
- Azathioprine: 2 mg/kg/day, methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week
- Where
- France
- Volunteers
- 126 people
- Sponsor
- Hospices Civils de Lyon
Wegener's Granulomatosis
Etanercept for Wegener's Granulomatosis
This study will determine if the drug etanercept, also called Enbrel, is effective in producing and maintaining remission (reduction of disease symptoms) of Wegener's granulomatosis (WG).
- Trial name
- NCT00005007
- Testing
- Etanercept
- Where
- 8 sites in United States
- Volunteers
- 181 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Granulomatosis With Polyangiitis, Microscopic Polyangiitis
Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study
Rituximab is the first drug approved by the United States Food and Drug Administration (FDA) for the treatment of patients with granulomatosis with polyangiitis (Wegener's granulomatosis) or microscopic polyangiitis.
- Trial name
- RAVELOS (NCT01586858)
- Testing
- Observational
- Where
- 8 sites in United States, Netherlands
- Volunteers
- 67 people
- Sponsor
- Johns Hopkins University
Granulomatosis With Polyangiitis
Comparison of Tofacitinib and Methotrexate in the Maintained Treatment of GPA
The aim of this study is to identify the optimal maintenance therapy for granulomatosis with polyangiitis (GPA) by comparing the MTX (standard regimen) with Tofacitinib in terms of efficacy, i.e. in preventing relapses.
- Trial name
- NCT04944524
- Testing
- Tofacitinib, Methotrexate
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Shanghai Zhongshan Hospital
Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA), Churg-Strauss Syndrome (CSS)
The ANCA Vasculitis Questionnaire (AAV-PRO©)
The aim of this project is to develop a disease specific patient reported outcome measure (PROM) for patients with AAV (the AAV-PRO).
- Conditions
- Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA), Churg-Strauss Syndrome (CSS), Granulomatosis With Polyangiitis (Wegener's) (GPA), Wegener Granulomatosis (WG)
- Trial name
- AAV-PRO (NCT02507024)
- Testing
- Online questionnaire
- Where
- 2 sites in United States
- Volunteers
- 280 people
- Sponsor
- University of Pennsylvania
ANCA Associated Vasculitis, Granulomatosis With Polyangiitis
Rituximab and Belimumab Combination Therapy in PR3 Vasculitis
Mechanistic study to assess whether dual B-cell immunotherapy by co-administration of rituximab and belimumab will result in improvements in biological endpoints, functional outcomes and clinical status compared to rituximab with…
- Trial name
- COMBIVAS (NCT03967925)
- Testing
- Belimumab, Rituximab, Prednisolone
- Where
- 6 sites in United Kingdom
- Volunteers
- 31 people
- Sponsor
- Rachel Jones
Churg-Strauss Syndrome, Eosinophilic Granulomatosis With Polyangiitis
NUCALA® Special Drug Use Investigation (EGPA, Long-term)
This study is a drug use investigation program of NUCALA. The objective of this study is to collect and assess information on the safety and effectiveness of the long-term use of NUCALA SC injection in daily clinical practice in…
- Trial name
- NCT03557060
- Testing
- Nucala
- Where
- Japan
- Volunteers
- 4,115 people
- Sponsor
- GlaxoSmithKline
ANCA-associated Vasculitis
Abatacept in ANCA Associated Vasculitis
The purpose of this study is to investigate whether abatacept can prevent relapse in patients with ANCA associated vasculitis(AAV). This is a randomised double blinded placebo controlled trial.
- Trial name
- ABAVAS (NCT00482066)
- Testing
- Abatacept (Orencia)
- Where
- United Kingdom
- Volunteers
- 7 people
- Sponsor
- Imperial College London
Sepsis, Pre-Eclampsia
Establishment of an ELISA for the Recognition of Procalcitonin Variants in Patients With Hyperprocalcitonemia.
Procalcitonin is a protein consisting of 116 amino-acids which can rapidly rise under inflammatory conditions and sepsis. More than 20 years ago it has been shown that dipeptidylpeptidase-4 (DPP-4) cleaves procalcitonin from the…
- Conditions
- Sepsis, Pre-Eclampsia, Granulomatosis With Polyangiitis, Microscopic Polyangiitis
- Trial name
- NCT05703802
- Testing
- Procalcitonin-variants ELISA-Assay
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- University Hospital Muenster
Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Giant Cell Arteritis
One-Time DNA Study for Vasculitis
The purpose of this study is to identify genes that increase the risk of developing vasculitis, a group of severe diseases that feature inflammation of blood vessels.
- Conditions
- Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Giant Cell Arteritis, Granulomatosis With Polyangiitis (Wegener's), Microscopic Polyangiitis
- Trial name
- NCT01241305
- Where
- 14 sites in United States, Canada and 1 more
- Volunteers
- 1,000 people
- Sponsor
- University of Pennsylvania
Eosinophilic Granulomatosis With Polyangiitis
A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA）
This study is a phase 2/3 clinical trial to evaluate the efficacy and safety of SHR-1703 in patients with EGPA.
- Trial name
- NCT05979051
- Testing
- SHR-1703, Mepolizumab Injection
- Where
- 2 sites in China
- Volunteers
- 166 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Vasculitis, Microscopic Polyangiitis
Alemtuzumab for ANCA Associated Refractory Vasculitis
Overview: This open label, randomized, multi-centre study will enroll and treat 24 patients with refractory AAV. Aims: To determine the clinical response and severe adverse event rates associated with alemtuzumab therapy among…
- Conditions
- Vasculitis, Microscopic Polyangiitis, Granulomatosis With Polyangiitis, Wegener's
- Trial name
- ALEVIATE (NCT01405807)
- Testing
- Alemtuzumab
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust